MedTrace Logo

Clinical Validation of InferRead Lung CT.AI

NCT04119960 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2020-07-28

No results posted yet for this study

Summary

Lung cancer is the second most common cause of cancer-related death in men and women. Early pulmonary nodule screening is an effective means to prevent lung cancer, which is no less important than the diagnosis and treatment of lung cancer. Early lung cancer screening has been investigated and applied as a medical practice. InferRead Lung CT.AI by Infervision is a dedicated post processing application that generates CADe marks as an overlay on the original CT series intended to aid the radiologist in the detection of pulmonary nodules. This study was designed to evaluate radiologists' performance in detecting actionable nodules on chest CT when aided by InferRead.

Conditions

Interventions

DEVICE

Aided read with InferRead Lung CT.AI

Radiologists read chest CT scans with the aid of InferRead Lung CT.AI

Sponsors & Collaborators

  • Infervision

    lead INDUSTRY

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-10
Primary Completion
2019-06-01
Completion
2019-10-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04119960 on ClinicalTrials.gov